Home » ANGIOTECH COMPLETES ACQUISITION OF AFMEDICA
ANGIOTECH COMPLETES ACQUISITION OF AFMEDICA
Angiotech Pharmaceuticals, Inc. today announced that it has completed its acquisition
of Afmedica, Inc., a private company developing perivascular technology using
the drug rapamycin to treat peripheral vascular disease, coronary artery disease
and end stage renal disease. The Afmedica transaction strengthens Angiotech's
leadership in peripheral by-pass surgery, where Angiotech is currently conducting
human clinical studies with its paclitaxel-eluting Vascular Wrap(TM) product
candidate and expects to present one year safety data from its European trial
this November at the Veith Conference in New York.
Canada
NewsWire
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
07May
-
14May
-
30May